- Home
- CMND vs APVO Comparison
CMND vs APVO Comparison
Compare CMND & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMND
- APVO
- Stock Information
- Founded
- CMND 2017
- APVO 2016
- Country
- CMND Canada
- APVO United States
- Employees
- CMND N/A
- APVO N/A
- Industry
- CMND Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- CMND Health Care
- APVO Health Care
- Exchange
- CMND Nasdaq
- APVO Nasdaq
- Market Cap
- CMND 4.8M
- APVO 4.1M
- IPO Year
- CMND N/A
- APVO N/A
- Fundamental
- Price
- CMND $0.85
- APVO $3.23
- Analyst Decision
- CMND
- APVO Strong Buy
- Analyst Count
- CMND 0
- APVO 1
- Target Price
- CMND N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- CMND 122.4K
- APVO 6.6M
- Earning Date
- CMND 06-12-2025
- APVO 08-07-2025
- Dividend Yield
- CMND N/A
- APVO N/A
- EPS Growth
- CMND N/A
- APVO N/A
- EPS
- CMND N/A
- APVO N/A
- Revenue
- CMND N/A
- APVO N/A
- Revenue This Year
- CMND N/A
- APVO N/A
- Revenue Next Year
- CMND N/A
- APVO N/A
- P/E Ratio
- CMND N/A
- APVO N/A
- Revenue Growth
- CMND N/A
- APVO N/A
- 52 Week Low
- CMND $0.80
- APVO $2.81
- 52 Week High
- CMND $2.30
- APVO $485.37
- Technical
- Relative Strength Index (RSI)
- CMND 41.60
- APVO 34.28
- Support Level
- CMND $0.83
- APVO $2.81
- Resistance Level
- CMND $0.93
- APVO $13.11
- Average True Range (ATR)
- CMND 0.06
- APVO 1.10
- MACD
- CMND 0.00
- APVO 0.30
- Stochastic Oscillator
- CMND 32.64
- APVO 4.08
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.